The fetal origins of the metabolic syndrome: can we intervene?

J Pregnancy. 2012:2012:482690. doi: 10.1155/2012/482690. Epub 2012 Sep 17.

Abstract

Epidemiological studies have suggested that metabolic programming begins during fetal life and adverse events in utero are a critical factor in the etiology of chronic diseases and overall health. While the underlying molecular mechanisms linking impaired fetal development to these adult diseases are being elucidated, little is known about how we can intervene early in life to diminish the incidence and severity of these long-term diseases. This paper highlights the latest clinical and pharmaceutical studies addressing how dietary intervention in fetal and neonatal life may be able to prevent aspects of the metabolic syndrome associated with IUGR pregnancies.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antioxidants / therapeutic use
  • Ascorbic Acid / therapeutic use
  • Diet Therapy
  • Dietary Supplements
  • Exenatide
  • Fatty Acids, Omega-3 / therapeutic use
  • Female
  • Fetal Growth Retardation / etiology
  • Fetal Growth Retardation / metabolism
  • Fetal Growth Retardation / prevention & control*
  • Folic Acid / therapeutic use
  • Humans
  • Hypoglycemic Agents / therapeutic use
  • Melatonin / therapeutic use
  • Metabolic Syndrome / etiology
  • Metabolic Syndrome / metabolism
  • Metabolic Syndrome / prevention & control*
  • Micronutrients / therapeutic use
  • Peptides / therapeutic use
  • Pregnancy
  • Prenatal Exposure Delayed Effects / etiology
  • Prenatal Exposure Delayed Effects / metabolism
  • Prenatal Exposure Delayed Effects / prevention & control*
  • Prenatal Nutritional Physiological Phenomena
  • Resveratrol
  • Stilbenes / therapeutic use
  • Venoms / therapeutic use

Substances

  • Antioxidants
  • Fatty Acids, Omega-3
  • Hypoglycemic Agents
  • Micronutrients
  • Peptides
  • Stilbenes
  • Venoms
  • Folic Acid
  • Exenatide
  • Melatonin
  • Ascorbic Acid
  • Resveratrol